EN DE
Watch Yonghe Medical Group Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Yonghe Medical Group Co Ltd (2279) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Yonghe Medical Group Co Ltd stock HK$3.81, price HK$2.21, upside +72.8%, quality 81 out of 100. Rating: strongly undervalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China · ISIN KYG5688E1008

YM Yonghe Medical Group Co Ltd logo Thin data Nov 14, 2026

Yonghe Medical Group Co Ltd

2279 · HK

Cheap (42% below fair value), strong company and rising price: meets all 3 rules.

Get notified free when this changes
Fair value HK$3.81 · Strongly undervalued 
Quality 81/100 
Rising price (uptrend) 
Generates free cash flow 
3.4% dividend yield · Well covered
Ranks above peers (13/13) 
Profit last quarter +169% vs. a year ago. 
Mixed Growth (revenue 5y +2.0 %/yr in CNY) 
Thin margins · 6.3% net margin (TTM) 
Moderate moat 46/100 · thin data
Changed on Nov 9: HK$5.32 → HK$3.81 
Thin data 
Watch Yonghe Medical Group Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$17.71 HK$0.6150 Fair Value HK$3.81 Dec 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.

How to read this chart

59‑month range HK$0.6150 – HK$17.71 · fair‑value band HK$2.86 – HK$4.76 · the HK$2.21 price screens below the HK$3.81 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 14, 2026.

Follow Yonghe Medical Group Co in your weekly email

Every Wednesday you see whether Yonghe Medical Group Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Yonghe Medical Group Co., Ltd. provides hair-related healthcare services in China. The company offers hair transplant, medical hair care, routine hair restoration, and other ancillary services.

Show moreShow less

It also engages in the provision of consulting services; investment and management; and medical wig products. Yonghe Medical Group Co., Ltd. was founded in 2005 and is headquartered in Beijing, China.

Stock analysis

Yonghe Medical Group Co Ltd (2279) currently trades at HK$2.21, while our model-based Fair Value estimate is HK$3.81, implying the stock looks roughly 42% undervalued today.

Show more

Valuation

Bull case: the Growth DCF group reads highest at a median of HK$11.46 per share, and 20 of the 23 models we run sit above the HK$2.21 price.

Bear case: the Asset-Based group reads lowest at HK$1.20, and 3 of the 23 models stay below the price. Data coverage for this calculation is low.

Scenario range: HK$2.86 (bear) to HK$4.76 (bull), the price of HK$2.21 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 81/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Yonghe Medical Group Co Ltd reported revenue of 1.8B CNY in FY2025 versus 2.2B CNY in FY2021, a compound −4.4%/yr. Reported net income was 73.7M CNY in FY2025, compounding −11.5%/yr from FY2021.

Key figures

Market cap HK$1.1B (≈ $141M) Micro · P/E ratio 7.8 · P/S ratio 0.32 · Dividend yield 3.4% · Net margin 4.1% · Return on equity 15.5% · Return on assets (EBIT) −4.4% (5-year average) · Operating margin 10.8%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 46 out of 100 (low confidence).

What moves the price

The share trades about 16% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −2% fair-value upside, at 73%, 2279 screens cheaper than that median.

Fair Value models

Bear HK$2.86 Fair Value HK$3.81 Bull HK$4.76
Price HK$2.21 · Upside +72.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF HK$11.18 HK$14.35 HK$18.16 80
Growth DCF HK$11.29 HK$14.14 HK$17.40 77
Residual Income HK$1.48 HK$1.58 HK$1.75 76
All 23 models by family
DCF Models
FCF DCF HK$11.18 HK$14.35 HK$18.16 80
Owner Earnings HK$9.74 HK$12.44 HK$15.68 75
5Y Revenue Exit HK$7.14 HK$8.58 HK$10.23 71
5Y EBITDA Exit HK$10.21 HK$14.08 HK$18.36 73
5Y P/E Exit HK$7.19 HK$8.68 HK$10.10 69
10Y Revenue Exit HK$8.79 HK$10.34 HK$12.07 66
10Y EBITDA Exit HK$10.54 HK$13.62 HK$17.31 67
10Y P/E Exit HK$8.88 HK$10.39 HK$11.98 63
Earnings-Based
Graham-Dodd HK$1.18 HK$2.91 HK$3.77 65
PEG = 1.0 HK$0.5300 HK$0.7500 HK$0.9800 57
EPV HK$2.70 HK$2.83 HK$2.94 70
Multiples
P/E Multiple HK$2.86 HK$3.81 HK$4.76 63
P/S Multiple HK$2.21 HK$2.94 HK$3.68 58
P/B Multiple HK$1.79 HK$2.38 HK$2.98 55
EV/EBIT HK$5.24 HK$6.44 HK$7.63 63
EV/EBITDA HK$10.61 HK$13.60 HK$16.59 64
EV/Revenue HK$4.21 HK$5.31 HK$6.41 52
Asset-Based
NCAV (Graham) HK$0.9000 HK$1.20 HK$1.80 51
Growth DCF
Growth DCF HK$11.29 HK$14.14 HK$17.40 77
Rev-Margin DCF HK$7.14 HK$8.78 HK$10.65 71
Economic Profit
Residual Income HK$1.48 HK$1.58 HK$1.75 76
ROIC Compounder HK$2.72 HK$2.88 HK$3.03 70
Growth Earnings
Growth-Adj P/E HK$2.19 HK$3.12 HK$4.06 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 81/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 57
How much profit the company makes from its sales and capital
Quality Growth 75
Are margins and returns getting better?
Cashflow 98
Do the profits arrive as real cash?
Financial strength 67
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 67
How calm the share price moves, does not count
Price momentum 39
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 57
Distance to the 52-week high, does not count
New shares 90
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 67/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−4.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year−8.3%
Dividend (yield on the price)3.4%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 7%

Watch 2279, get fair value alerts →

Compare Yonghe Medical Group Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 249 stocks

Beats the industry median on 13/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 81 · Top 25%
Fair Value upside +72.8% · Top 25%
Profitability
Return on equity (12 months) 15.5% · Above median
Return on assets 4.3% · Above median
Net margin (12 months) 6.3% · Above median
Operating margin (12 months) 10.8% · Above median
Growth and dividend
Revenue growth (quarter YoY) 13.8% · Above median
Dividend yield (12 months) 3.4% · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (12 months) 7.8× · Cheapest 25%
P/B 1.19× · Cheaper than median
P/S (12 months) 0.49× · Cheapest 25%
Price / free cash flow (fiscal year) 2.0× · Cheapest 25%
EV/EBITDA 0.8× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 34
FUTURE (revenue growth)69 · sector 31
PAST (return on equity)62 · sector 31
HEALTH (low debt)0 · sector 90
DIVIDEND (yield)69 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Fresenius Medical Care AG FMS $22.03 $45.73 +108% vs 2279
DaVita Inc DVA $174.56 $218.90 +25% vs 2279
Aier Eye Hospital Group 300015 ¥8.84 ¥10.88 +23% vs 2279
HCA Healthcare, Inc HCA $499.05 $547.34 +10% vs 2279
Tenet Healthcare Corporation THC $286.03 $279.20 −2% vs 2279
The Ensign Group ENSG $188.41 $140.09 −26% vs 2279
Encompass Health Corporation EHC $140.99 $94.81 −33% vs 2279
Fresenius SE FRE €53.62 €34.77 −35% vs 2279
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,526 ₹5,234 −39% vs 2279
Dr. Sulaiman Al Habib Medical Services Group 4013 212.10 SAR 109.45 SAR −48% vs 2279

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Yonghe Medical Group Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Yonghe Medical Group Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2279

Frequently asked questions

Is Yonghe Medical Group Co Ltd (2279) overvalued or undervalued?
As of Nov 14, 2026, our model estimates a fair value of HK$3.81 versus a price of HK$2.21, about +73% upside (undervalued).
What is the fair value of 2279?
Our model-based fair value for Yonghe Medical Group Co Ltd is HK$3.81 (as of Nov 14, 2026), built from audited fundamentals. The current price: HK$2.21.
What is the quality score of 2279?
Yonghe Medical Group Co Ltd has a Quality Score of 81/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Yonghe Medical Group Co Ltd (2279)?
Our model-based price target is the fair value of HK$3.81 (as of Nov 14, 2026) from 23 valuation models. Cautious scenario HK$2.86, optimistic scenario HK$4.76. It is a calculation from audited fundamentals, not an analyst target.
What is the Yonghe Medical Group Co Ltd stock forecast for 2026?
Our models put fair value at HK$3.81, about +73% upside versus a price of HK$2.21 (undervalued). Cautious scenario HK$2.86, optimistic scenario HK$4.76. The calculation is refreshed regularly with new filings.
What is the revenue of Yonghe Medical Group Co Ltd (2279)?
Yonghe Medical Group Co Ltd reported trailing-twelve-month revenue of about 1.9B CNY (latest available figure, as of Nov 14, 2026).
Does Yonghe Medical Group Co Ltd pay a dividend?
Yonghe Medical Group Co Ltd currently shows a dividend yield of 3.45% relative to its recent price (as of Nov 14, 2026).
How much is the dividend of Yonghe Medical Group Co Ltd (2279) and when is the ex-dividend date?
Yonghe Medical Group Co Ltd pays a dividend of HK$0.076 per share a year, a dividend yield of 3.4%. The last ex-dividend date was May 26, 2026. The payout ratio is 43.8% of earnings. Free cash flow covers the dividend 14.75 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What is the intrinsic value of Yonghe Medical Group Co Ltd (2279)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Yonghe Medical Group Co Ltd it is HK$3.81 per share (as of Nov 14, 2026), against a price of HK$2.21. It is the blended result of 23 valuation models in 7 families (DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Yonghe Medical Group Co Ltd stock overvalued or undervalued in 2026?
As of Nov 14, 2026, 2279 trades below its calculated fair value: price HK$2.21, fair value HK$3.81, a gap of about +73% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2279?
No. The price is what the market pays today (HK$2.21); the fair value is what the company's own numbers justify (HK$3.81). For Yonghe Medical Group Co Ltd the two are HK$1.61 per share apart. That gap is exactly why we show both numbers side by side.
How much is Yonghe Medical Group Co Ltd worth?
The market values Yonghe Medical Group Co Ltd at about HK$1.1B (market capitalisation, as of Nov 14, 2026). Per share that is HK$2.21; our models calculate a fair value of HK$3.81 per share.
What do the bullish and bearish scenarios say about 2279?
Our models span a range for Yonghe Medical Group Co Ltd: cautious scenario HK$2.86, base HK$3.81, optimistic HK$4.76 per share (as of Nov 14, 2026, price HK$2.21). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 2279?
Yonghe Medical Group Co Ltd trades at a price-to-earnings ratio of 7.8 (as of Nov 14, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of HK$3.81 is built from several models across several years. Other multiples: P/B 1.2, P/S 0.5, EV/EBITDA 0.8.
How solid is the balance sheet of Yonghe Medical Group Co Ltd (2279)?
Balance-sheet figures for Yonghe Medical Group Co Ltd (as of Nov 14, 2026): return on equity 15.5%. They feed the Quality Score of 81/100, which measures business quality independently of the share price.
How far is 2279 from its 52-week high?
Yonghe Medical Group Co Ltd trades at HK$2.21, about 16% below its 52-week high of HK$2.62 and 42% above the low of HK$1.56 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$3.81 is for.
Which stocks are comparable to Yonghe Medical Group Co Ltd?
From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Tenet Healthcare Corporation, Dr. Sulaiman Al Habib Medical Services Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Yonghe Medical Group Co Ltd stock attractive at the current price?
The data as of Nov 14, 2026: price HK$2.21, calculated fair value HK$3.81 (+73%), Quality Score 81/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 2279 calculated?
We run Yonghe Medical Group Co Ltd through 23 models from 7 families: DCF Models, Earnings-Based, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of HK$3.81 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Yonghe Medical Group Co Ltd currently trades 42% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Yonghe Medical Group Co Ltd (2279)?
The closing price on Nov 13, 2026 was HK$2.21. Our model-based fair value is HK$3.81, about +73% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Yonghe Medical Group Co Ltd right now?
The rarer combination: high quality (81/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (HK$2.86). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Yonghe Medical Group Co Ltd

How large is the market capitalisation of Yonghe Medical Group Co Ltd (2279)?
The market capitalisation of Yonghe Medical Group Co Ltd is HK$1.1B (≈ $141M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Yonghe Medical Group Co Ltd (2279)?
The price-to-sales ratio of Yonghe Medical Group Co Ltd is 0.32 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Yonghe Medical Group Co Ltd (2279)?
The dividend yield of Yonghe Medical Group Co Ltd is 3.4%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Yonghe Medical Group Co Ltd (2279)?
The net margin of Yonghe Medical Group Co Ltd is 4.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Yonghe Medical Group Co Ltd (2279)?
The return on equity (ROE) of Yonghe Medical Group Co Ltd is 15.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Yonghe Medical Group Co Ltd (2279)?
On an EBIT basis the return on assets of Yonghe Medical Group Co Ltd is −4.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Yonghe Medical Group Co Ltd (2279)?
The operating margin of Yonghe Medical Group Co Ltd is 10.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Yonghe Medical Group Co Ltd (2279)?
Revenue at Yonghe Medical Group Co Ltd is growing 13.8% versus a year earlier (3y avg +8.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Yonghe Medical Group Co Ltd (2279)?
Earnings per share at Yonghe Medical Group Co Ltd are growing 169% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Yonghe Medical Group Co Ltd (2279) generate?
The free cash flow of Yonghe Medical Group Co Ltd is 477M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Yonghe Medical Group Co Ltd in the live analysis

One click puts Yonghe Medical Group Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.